Download PDF
Hamostaseologie 2015; 35(04): 311-318
DOI: 10.5482/HAMO-14-11-0064
Review
Schattauer GmbH

Management of acquired haemophilia A

Management der erworbenen Hämophilie
A. Tiede
1   Department of Haematology, Haemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
,
R. E. Scharf
2   Department of Clinical and Experimental Haemostasis, Haemotherapy and Transfusion Medicine, Heinrich Heine University Medical Centre, Düsseldorf, Germany
,
C. Dobbelstein
1   Department of Haematology, Haemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
,
S. Werwitzke
1   Department of Haematology, Haemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
› Author AffiliationsThe authors are grateful to all participating centres of the GTH-AH 01/2010 study for their contribution. Funding for this study was obtained from GTH e. V. and by unrestricted educational grants from Novo Nordisk Pharma GmbH, Mainz, Germany, and Baxter Deutschland GmbH, Unterschleißheim, Germany.
Further Information

Publication History

received: 14 November 2014

accepted in revised form: 11 January 2014

Publication Date:
28 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

Acquired haemophilia A (AHA) is caused by autoantibody inhibitors of coagulation factor VIII (FVIII : C). Recent onset of bleeds and isolated prolongation of the activated partial thromboplastin time (aPTT) are characteristic features of the disorder. Reduced FVIII : C activity and a detectable FVIII : C inhibitor in the Bethesda assay confirm the diagnosis. Patients should be referred to expert centres, whenever possible, and invasive procedures with a high risk of bleeding must be avoided, until haemostasis has been secured by adequate therapy.

Bypassing agents capable of inducing sufficient thrombin formation in the presence of FVIII : C inhibitors are treatment of choice, including currently available recombinant factor VIIa (NovoSeven™) and activated prothrombin complex concentrate (FEIBA™). These agents represent first line therapy to control acute or severe bleeds. To eradicate inhibitors, immunosuppressive treatment (IST) is indicated in patients with AHA. Glucocorticoids, cytotoxic agents and rituximab are most widely used. However, an ideal IST regimen has not been established so far. Adverse events of IST, including infections as the foremost cause death, are frequent complications in AHA.

Zusammenfassung

Die erworbene Hämophilie A wird durch Auto - antikörper gegen den Gerinnungsfaktor VIII (FVIII : C) verursacht. Eine neu aufgetretene Blutungsneigung und isolierte Verlängerung der aktivierten partiellen Thromboplastinzeit (aPTT) sind Hinweise auf die Erkrankung. Die Diagnose wird durch reduzierte FVIII : C-Aktivität und im Bethesda-Test nachweisbaren FVIII : C- Inhibitor bestätigt. Die Patienten sollten in erfahrenen Zentren behandelt werden. Invasive Prozeduren mit hohem Blutungsrisiko sind unbedingt aufzuschieben, bis die Hämostase durch adäquate Behandlung wieder gewährleistet ist.

Therapie der Wahl ist der Einsatz so genannter Bypass-Produkte, die auch in Anwesenheit von FVIII:C-Inhibitoren eine ausreichende Thrombinbildung bewirken. Zur Verfügung stehen gegenwärtig rekombinanter Faktor VIIa (NovoSeven®) und aktiviertes Prothrombinkomplex- Konzentrat (FEIBA®). Bei akuten oder schweren Blutungen haben sich diese Medikamente als Erstlinientherapie bewährt. Zur Eradikation des Inhibitors sollten Patienten mit erworbener Hämophilie eine immunsuppressive Therapie (IST) erhalten. Glucokortikoide, Zytostatika und Rituximab sind die am häufigsten eingesetzten Substanzen. Allerdings existiert bislang kein optimales IST-Regime. Unerwünschte Arzneimittelwirkungen der IST, vor allem Infektionen als häufigster Todesursache, sind oftmals auftretende Komplikationen bei Patienten mit erworbener Hämophilie.

Keywords

Factor VIII : C - inhibitor - bleeding - recombinant factor VIIa - activated prothrombin complex concentrate - immunosuppression

Schlüsselwörter

Faktor VIII : C - Hemmkörper - Blutungsneigung - rekombinanter Faktor VIIa - aktiviertes Prothrombi nkomplex-Konzentrat - Immunsuppression
 

  • References

  • 1 Collins PW, Percy CL. Advances in the understanding of acquired haemophilia A. Br J Haematol 2010; 148: 183-194.
    CrossrefPubMedGoogle Scholar
  • 2 Baudo F, Caimi T, de Cataldo F. Diagnosis and treatment of acquired haemophilia. Haemophilia 2010; 16: 102-106.
    CrossrefPubMedGoogle Scholar
  • 3 Knoebl P, Marco P, Baudo F. et al. Demographic and clinical data in acquired hemophilia A. J Thromb Haemost 2012; 10: 622-631.
    CrossrefPubMedGoogle Scholar
  • 4 Gheisari R, Bomke B, Hoffmann T. et al. Clinical features and outcome of acquired haemophilia A. Hämostaseologie 2010; 30: 156-161.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Baudo F, Collins P, Huth-Kuhne A. et al. Management of bleeding in acquired hemophilia A. Blood 2012; 120: 39-46.
    CrossrefPubMedGoogle Scholar
  • 6 Tiede A, Werwitzke S, Scharf RE. Laboratory diagnosis of acquired hemophilia A. Semin Thromb Hemost 2014; 40: 803-811.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Pengo V, Tripodi A, Reber G. et al. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009; 07: 1737-1740.
    CrossrefPubMedGoogle Scholar
  • 8 Tripodi A, Mancuso ME, Chantarangkul V. et al. Lupus anticoagulants and their relationship with the inhibitors against coagulation factor VIII. Clin Chem 2005; 51: 1883-1885.
    CrossrefPubMedGoogle Scholar
  • 9 Huth-Kuhne A, Baudo F, Collins P. et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica 2009; 94: 566-575.
    CrossrefPubMedGoogle Scholar
  • 10 Sumner MJ, Geldziler BD, Pedersen M. et al. Treatment of acquired haemophilia with recombinant activated FVII. Haemophilia 2007; 13: 451-461.
    CrossrefPubMedGoogle Scholar
  • 11 Hay CR, Negrier C, Ludlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study. Thromb Haemost 1997; 78: 1463-1467.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Sallah S. Treatment of acquired haemophilia with factor eight inhibitor bypassing activity. Haemophilia 2004; 10: 169-173.
    PubMedGoogle Scholar
  • 13 Holmstrom M, Tran HT, Holme PA. Combined treatment with APCC and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A. Haemophilia 2012; 18: 544-549.
    CrossrefPubMedGoogle Scholar
  • 14 McCain S, Gull S, Ahmad J. et al. Acquired hemophilia A as a cause of acute upper gastrointestinal hemorrhage. BMJ Case Rep. 2014: 2014.
    PubMedGoogle Scholar
  • 15 Taparia M, Cordingley FT, Leahy MF. Pulmonary embolism associated with tranexamic acid in severe acquired haemophilia. Eur J Haematol 2002; 68: 307-309.
    CrossrefPubMedGoogle Scholar
  • 16 Lottenberg R, Kentro TB, Kitchens CS. Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. Arch Intern Med 1987; 147: 1077-1081.
    CrossrefPubMedGoogle Scholar
  • 17 Delgado J, Jimenez-Yuste V, Hernandez-Navarro F. et al. Acquired haemophilia: review and metaanalysis focused on therapy and prognostic factors. Br J Haematol 2003; 121: 21-35.
    CrossrefPubMedGoogle Scholar
  • 18 Collins P, Macartney N, Davies R. et al. A population based, unselected, consecutive cohort of patients with acquired haemophilia A. Br J Haematol 2004; 124: 86-90.
    CrossrefPubMedGoogle Scholar
  • 19 Tiede A, Huth-Kuhne A, Oldenburg J. et al. Immunosuppressive treatment for acquired haemophilia: current practice and future directions in Germany, Austria and Switzerland. Ann Hematol 2009; 88: 365-370.
    PubMedGoogle Scholar
  • 20 Collins PW. Management of acquired haemophilia A. J Thromb Haemost 2011; 09 (Suppl. 01) 226-235.
    PubMedGoogle Scholar
  • 21 Collins PW, Hirsch S, Baglin TP. et al. Acquired hemophilia A in the United Kingdom. Blood 2007; 109: 1870-1877.
    CrossrefPubMedGoogle Scholar
  • 22 Collins P, Baudo F, Knoebl P. et al. Immunosuppression for acquired hemophilia A. Blood 2012; 120: 47-55.
    CrossrefPubMedGoogle Scholar
  • 23 Collins P, Baudo F, Huth-Kuhne A. et al. Consensus recommendations for the diagnosis and treatment of acquired hemophilia A. BMC Res Notes 2010; 03: 161.
    CrossrefPubMedGoogle Scholar
  • 24 Lian EC, Larcada AF, Chiu AY. Combination immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor. Ann Intern Med 1989; 110: 774-778.
    CrossrefPubMedGoogle Scholar
  • 25 Nemes L, Pitlik E. New protocol for immune tolerance induction in acquired hemophilia. Haematologica 2000; 85 (Suppl. 10) 64-68.
    PubMedGoogle Scholar
  • 26 Zeitler H, Ulrich-Merzenich G, Hess L. et al. Treatment of acquired hemophilia by the Bonn-Malmo Protocol. Blood 2005; 105: 2287-2293.
    CrossrefPubMedGoogle Scholar
  • 27 Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost 1981; 45: 200-203.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Tiede A, Klamroth R, Scharf RE. et al. Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. Blood 2015; 125: 1091-1097.
    CrossrefPubMedGoogle Scholar
  • 29 Barrow RT, Lollar P. Neutralization of antifactor VIII inhibitors by recombinant porcine factor VIII. J Thromb Haemost 2006; 04: 2223-2229.
    CrossrefPubMedGoogle Scholar
  • 30 Lozier JN, Nghiem K, Lee M. et al. Acquired haemophilia A after stem cell transplant for sickle cell disease. Haemophilia 2014; 20: e185-e188.
    CrossrefPubMedGoogle Scholar